Arca
Skip to content
Tools
Tools

PDE3A, PDE3B: Phosphodiesterase 3

Family in Homo sapiens that 7 drugs act on.

  • Drugs that act on it: 7
  • Approved: 5
  • In phases 1 to 3: 2
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on PDE3A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6
  • Protein or peptide 1

Approved5

  • Anagrelide
  • Ensifentrine
  • Enoximone
  • Theophylline anhydrous
  • Theophylline glycinate

Phase 31

  • Levosimendan

Phase 21

  • K-134

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 3 inhibitor.
    AnagrelideApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor4
    EnsifentrineApprovedMerck & Co. (MSD)Small moleculeInhibitor3
    EnoximoneApprovedGilead SciencesSmall moleculeInhibitor1
    Theophylline anhydrousApprovedOrganonProtein or peptideInhibitor1
    Theophylline glycinateApprovedCent PharmaceuticalsSmall moleculeInhibitor0
    LevosimendanPhase 3Tenax TherapeuticsSmall moleculeInhibitor9
    K-134Phase 2Kowa Research Institute, Inc.Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov.
    The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary ThromboendarterectomyLevosimendanNot applicableRecruitingMeshalkin Research Institute of Pathology of CirculationNov 4, 2026
    Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)EnsifentrinePhase 3RecruitingMerck Sharp & Dohme LLCOct 15, 2026
    Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility StudyLevosimendanNot applicableRecruitingNiguarda HospitalJun 24, 2026
    Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture HeadacheTheophylline anhydrousNot applicableRecruitingTanta UniversityApr 7, 2026
    Long-Term Open-Label Extension Study of Oral LevosimendanLevosimendanPhase 3Enrolling by invitationTenax Therapeutics, Inc.Feb 27, 2026
    LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2LevosimendanPhase 3Active, not recruitingTenax Therapeutics, Inc.Dec 17, 2025
    Levosimendan in Acute Decompensated Heart FailureLevosimendanPhase 2 / Phase 3Not yet recruitingChittagong Medical CollegeDec 4, 2025
    Shorter Weaning From Invasive Ventilation With LevosimendanLevosimendanPhase 4RecruitingRadboud University Medical CenterAug 5, 2025
    Pharmacokinetic Modelling of Levosimendan in AdultsLevosimendan—Not yet recruitingUniversity Hospital, RouenMay 29, 2025
    A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisEnsifentrinePhase 2RecruitingVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAAug 19, 2024
    A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)AnagrelidePhase 3Active, not recruitingMerck Sharp & Dohme LLCOct 12, 2023
    LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFLevosimendanPhase 3Active, not recruitingTenax Therapeutics, Inc.Aug 9, 2023
    Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)EnsifentrinePhase 2Active, not recruitingVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAMar 8, 2022
    Unloading in Heart Failure Cardiogenic ShockEnoximoneNot applicableNot yet recruitingAmsterdam UMC, location VUmcOct 1, 2021
    A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisAnagrelidePhase 2Active, not recruitingKaryopharm Therapeutics IncSep 24, 2020
    Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceAnagrelidePhase 3Active, not recruitingPharmaEssentiaFeb 26, 2020
    The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaAnagrelidePhase 2Active, not recruitingRWTH Aachen UniversityOct 16, 2015

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094125, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.